A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease ...
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...
Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...
SYDNEY--Pharmaceutical company CSL on Monday downgraded its annual earnings guidance and signaled another $5 billion of pretax impairments, including for the Vifor business that it acquired for $11.7 ...
CSL reveals lower FY26 earnings guidance and significant asset impairments. The post CSL cuts FY26 guidance, flags $5bn in impairments appeared first on The Motley Fool Australia.
Grifols (GRFS) outlook: discounted valuation, refinancing to 2028, rising margins and FCF, and plasma scale tailwinds.
CSL shares crash after another profit warning rocks investor confidence. The post CSL shares suffer their biggest one-day crash ever! What just went wrong? appeared first on The Motley Fool Australia.
CSL and Healius dragged the healthcare sector sharply lower this week, but EBR Systems and Blinklab still gave investors something ... Read More The post Scott Power: CSL bleeds in ‘shocking week’ for ...
You will be redirected to our submission process. Respiratory diseases remain among the leading causes of morbidity and mortality worldwide, imposing a substantial burden on health systems and ...
Amid the drama at the biotech, a new figure has stepped up right as the company needs a new long-term chief executive and chairman. Brian McNamee is CSL’s immovable object and unstoppable force. But ...
Three dosing levels of enpatoran each reduced disease activity among patients with skin manifestations of cutaneous or ...
In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results